Solace Pharmaceuticals, Inc.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent,Versus Placebo in the Treatment of Post Herpetic Neuralgia